THBS1 inhibits tumor growth, cell migration, and neovascularization, and low expression of this gene is related to poor prognoses in NSCLC [74], which indicated that THBS1+ EndMT-like cells may be related to the prognosis of NSCLC, and SMI assisting PD-1 inhibitor may improve the prognosis of NSCLC by increasing the proportion of THBS1+ EndMT-like cells. The gene discussed is THBS1; the disease is non-small cell lung carcinoma.